The latest price target for Singular Genomics Sys (NASDAQ:OMIC) was reported by Goldman Sachs on July 9, 2024. The analyst firm set a price target for $6.50 expecting OMIC to fall to within 12 months (a possible -69.77% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Singular Genomics Sys (NASDAQ:OMIC) was provided by Goldman Sachs, and Singular Genomics Sys maintained their neutral rating.

The last upgrade for Singular Genomics Systems Inc happened on January 7, 2022 when B of A Securities raised their price target to $21. B of A Securities previously had a neutral for Singular Genomics Systems Inc.

The last downgrade for Singular Genomics Systems Inc happened on August 17, 2022 when UBS changed their price target from $10 to $4.5 for Singular Genomics Systems Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Singular Genomics Sys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Singular Genomics Sys was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.

While ratings are subjective and will change, the latest Singular Genomics Sys (OMIC) rating was a maintained with a price target of $22.50 to $6.50. The current price Singular Genomics Sys (OMIC) is trading at is $21.50, which is out of the analyst’s predicted range.